stockrowPliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022.
- EPS
- +49.3%
- Free cash flow
- +68.6%
Quarter to June 2026, against a year earlier
Follow PLRX
Alert me
Pliant Therapeutics, Inc. (PLRX) EV/Sales
As of 6 November 2026, Pliant Therapeutics, Inc. (PLRX) trades at a EV/Sales of −15.4×. Over the past ten years it has ranged from −48.5× (March 2025) to 133× (January 2024); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 113× | 130.36% |
| FY2022 | 49.3× | 29.21% |
| FY2021 | 38.1× | 666.21% |
| FY2020 | 5.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 105× | 10.86% |
| Mar 2023 | 94.6× | 92.00% |
| Dec 2022 | 49.3× | (23.68%) |
| Sep 2022 | 64.5× | 367.25% |
| 11 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PLRX Pliant Therapeutics, Inc. | −15.4× |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | 2.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)